Major disappointment for Targacept and AstraZeneca in Phase III depression trial
This article was originally published in Scrip
Executive Summary
Targacept stock will take a battering later today on news that its lead drug candidate TC-5214, which is being developed in collaboration with AstraZeneca as a treatment for major depressive disorder (MDD), did not meet its primary endpoint in a Phase III trial.